Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


MorphoSys to Present at Two Upcoming Investor Conferences

MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 11/09/12 -- The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present at two upcoming international investor conferences:

Deutsches Eigenkapitalforum
Date: November 13, 2012, 1:30 pm CET (7:30 am EST, 12:30 pm GMT)
Venue: Frankfurt, Germany
Participants:    Jens Holstein, CFO of MorphoSys AG
                 Dr. Claudia Gutjahr-Löser, Head of Corporate
                 Communications & IR

Jefferies Global Healthcare Conference
Date: November 15, 2012, 2:20 pm GMT (9:20 am EST, 3:20 pm CET)
Venue: London, UK
Participants:    Jens Holstein, CFO of MorphoSys AG
                 Dr. Claudia Gutjahr-Löser, Head of Corporate
                 Communications & IR

American College for Rheumatology (ACR) Annual Meeting
Date: November 13, 2012, 3:00 pm EST (10:00 pm GST, 9:00 pm CET)
Venue: Washington, USA
Prof. Harald Burkhardt, Professor of Rheumatology and Head of the Division
of Rheumatology at Goethe University Frankfurt will present data from the
phase 1b/2a clinical trial evaluating MorphoSys's proprietary HuCAL
antibody MOR103 in rheumatoid arthritis.

The PDF version of the presentation will be provided at www.morphosys.com. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1656672/535663.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1656672]

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
In the business world, it’s hard to throw a rock without hitting a compliance requirement. All must be obeyed, but some call for a high level of control and auditability. Governing bodies are exerting their authority like never before, increasing the number of auditors and handing out ...
One of the many questions that companies face when introducing new enterprise systems either to provide new functionality or incorporate legacy systems from a merger or acquisition is "How do we identify and manage access rights?" Not only do new access approval processes need to be e...
One of the key driving factors behind the various web/mobile performance initiatives is the fact that end-users’ tolerance for latency has nose-dived. Several studies have been published whereby it has been demonstrated that poor performance routinely impacts the bottom line, viz,. # u...
The world of business is changing. Disruptive shifts in power are forcing everyone to question the established status quo. In particular, savvy chief executives are tasking IT organizations to help create compelling customer experiences, support new business models and adopt agile oper...
The burgeoning trends around DevOps are translating into new types of IT infrastructure that both developers and operators can take advantage of. The next BriefingsDirect Voice of the Customer thought leadership discussion focuses on the burgeoning trends around DevOps and how that’s ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE